Human papillomaviruses in the pathogenesis of anogenital cancer.
about
The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteinsGps2, a protein partner for human papillomavirus E6 proteinsInteraction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocationEffects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complexDifferential expression of the human ST5 gene in HeLa-fibroblast hybrid cell lines mediated by YY1: evidence that YY1 plays a part in tumor suppressionModulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoproteinHuman herpesvirus 6Human papilloma viruses and cervical tumours: mapping of integration sites and analysis of adjacent cellular sequencesThe Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in AfricaThe antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epitheliumA Functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G boxCervical carcinoma in Surinam. Incidence and staging of cervical carcinoma between 1989 and 1994.KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma.In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response.Multiple-integrations of HPV16 genome and altered transcription of viral oncogenes and cellular genes are associated with the development of cervical cancerComparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer.Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation.Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation.Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatmentInhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus.Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.Clinical applications of a peptide-based vaccine for glioblastoma.Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway.Genetic analysis of the human papillomavirus type 31 differentiation-dependent late promoter.Novel binding sites for regulatory factors in the human papillomavirus type 18 enhancer and promoter identified by in vivo footprintingOverexpression of C/EBPbeta represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein.Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16.Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b.Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions.Correlation of DNA ploidy with progression of cervical cancerThe role of the E6-p53 interaction in the molecular pathogenesis of HPV.Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein.Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor sitePapillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.Two polymorphic variants of wild-type p53 differ biochemically and biologically.Small tumor virus genomes are integrated near nuclear matrix attachment regions in transformed cells.Usage of heparan sulfate, integrins, and FAK in HPV16 infection.
P2860
Q24315710-F6FA46D3-C235-410C-9BAB-62EB6BEA334CQ24529012-41791A06-E2E4-46D5-8295-81DA00C9974AQ24529358-D11D2F03-F718-4B0A-BD6E-DDF7BCAA7104Q24532787-81D4A1A9-B8EB-40CF-AFED-5194B9B77B78Q24544034-93117981-80D7-45C5-9D63-6610934FFC25Q24676090-1A6ED672-3C7D-49E1-BAC5-133DB0060ED6Q24683663-9344AE1E-AB6D-45A9-B57A-7FC1B1BA4016Q24794024-A4B909ED-3EBE-44D2-9C59-9788F34F848EQ26799584-60257BBC-0722-4DDB-9568-75CAD3420845Q27480447-C747E69B-5055-46C3-B5E2-93F1966A2869Q28212996-404D4342-F6B8-455D-A491-C9C784E21288Q28291338-37EEEB91-C814-473A-9BED-AB41681F5C0EQ29354137-E95E3948-7030-45B6-A098-F2CDAE37433AQ30444871-0A814765-122C-4C2D-B644-83EBE2FD6043Q30661799-E638C9A2-B743-412A-885B-DFB8AB273C41Q31172479-911EE15B-07FF-4C75-9455-00914EFD3291Q33189224-142868DA-F9F0-4ED7-BF69-591EB897D30FQ33292273-70979B8C-C68A-44F2-A65E-2093E251DB33Q33292379-999CCE25-A54A-43B7-A705-B98459C2D07BQ33347618-B3F69EA8-67CB-4024-BD2E-89C0962A619EQ33604135-DE368E82-D2E4-47DD-8E2E-9D19757E1553Q33609914-7162FB88-9DA9-403E-9C6C-37124A85E49FQ33650663-9A2B1AC1-9836-42FE-9B82-966F72FF32BAQ33668575-B9C96D04-F06D-4770-9C5C-4ECE8AB1C2E1Q33713511-F0CAEF2C-C3B9-4481-8567-245E0AF921B2Q33737684-C2A06D40-4C98-4153-942F-59B9F685C7B7Q33782147-CF66151A-4961-4AC2-8382-6C7BB7AD0EAEQ33782394-FFA1F554-BDD3-407B-B105-5C8E7A66EBA6Q33782472-1873CFEB-33B8-42C6-9B30-8A539D444822Q33783002-76BC4AAC-F0E8-4A68-85B8-A9E73F4CB255Q33784825-80F90108-1E1E-47AC-9173-A57EB32F2885Q33807648-8A0A6FA3-5CC6-4EBB-878E-D71E89CE36E4Q33807833-51E66910-FB4C-44C6-ACB5-74671760B073Q33835617-18009FE1-F07D-4D59-955F-07C65E609F84Q33840150-DF20D5FC-3AB2-4851-9845-18C4938424B4Q33846428-FBF6887F-CC8D-454A-B8D9-9C00A9EEB943Q33847557-C9687E95-7B78-4078-855F-B9B015F3A6C3Q33868530-72182E77-D6C9-4273-8BED-62C91A08198EQ33870418-4FDE3769-D1A3-4360-8BDE-9FE924040760Q33905761-7BAD2A59-7D6D-4EDA-9F9C-2B7979091896
P2860
Human papillomaviruses in the pathogenesis of anogenital cancer.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Human papillomaviruses in the pathogenesis of anogenital cancer.
@ast
Human papillomaviruses in the pathogenesis of anogenital cancer.
@en
type
label
Human papillomaviruses in the pathogenesis of anogenital cancer.
@ast
Human papillomaviruses in the pathogenesis of anogenital cancer.
@en
prefLabel
Human papillomaviruses in the pathogenesis of anogenital cancer.
@ast
Human papillomaviruses in the pathogenesis of anogenital cancer.
@en
P1433
P1476
Human papillomaviruses in the pathogenesis of anogenital cancer.
@en
P356
10.1016/0042-6822(91)90816-T
P407
P577
1991-09-01T00:00:00Z